Semaglutide represents the superior choice for patients seeking maximum weight loss efficacy and who can tolerate gastrointestinal side effects during the initial months of treatment
On average, patients return to their pre-treatment weight within 1.7 years of stopping any weight management medication, including semaglutide and tirzepatide
Typical weight loss goals when taking medications are one pound of weight loss per week, with a 4% to 5% weight loss achieved after three to six months of taking the medication
The most common side effects reported in trials include mild to moderate gastrointestinal issues: nausea, diarrhea, vomiting, and constipation
GLP-1 r ett sdant inkretinhormon, och GIP r ett annat
Author: Shelley Jeon, PharmD Candidate 2025, Northeastern University School of Pharmacy Reviewer: Courtney Cameron, PharmD, BCACP What data are available on weight regain after stopping GLP-1 receptor agonists